Cardiovascular disease prevention is limited less by knowledge than by timing: cumulative lifetime exposure to apoB-containing lipoproteins determines atherosclerotic risk, which argues for intervention in the third and fourth decades rather than after plaque is established. The discussion extends to APOE4 status, the overlap between vascular and neurodegenerative risk, and emerging lipid-lowering therapies including Lp(a)-directed agents.
Key Points
- Cumulative LDL exposure, not current level, drives atherosclerotic risk
- Early intervention in the 30s outperforms late-stage risk management
- APOE4 links lipid handling to both vascular and cognitive decline
Longevity Analysis
Arterial damage accumulates silently for decades before any measurable event, which makes standard 10-year risk calculators poorly suited to anyone interested in a long healthspan. Reading apoB and Lp(a) early, alongside APOE4 status, converts a vague future probability into an actionable present-day number — and the same lipid biology that determines how vessels carry blood also shapes how the brain clears and regenerates. The decisive variable is sustained adherence across decades, not the sophistication of any single agent.
Original published by Peter Attia MD, by Peter Attia.